Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Core Insights - Context Therapeutics Inc. is advancing T cell engaging bispecific antibodies for solid tumors, specifically highlighting its CT-95 and CT-202 programs at the SITC 40th Annual Meeting [1][2] Group 1: CT-95 Program - CT-95 is a mesothelin x CD3 bispecific TCE designed to redirect T-cell-mediated lysis towards malignant cells expressing mesothelin, which is overexpressed in approximately 30% of cancers [4] - The clinical trial for CT-95 is ongoing in the US, with 6 patients enrolled as of October 30, 2025, and currently enrolling Cohort 3 with a priming dose of 0.18 µg/kg and a full dose of 0.6 µg/kg [7] - No cytokine release syndrome greater than Grade 2 has been observed, and no dose limiting toxicity has been reported, allowing for continued dose escalation towards target levels [7] Group 2: CT-202 Program - CT-202 targets Nectin-4, a protein overexpressed in various solid tumors, including bladder, colorectal, lung, and breast cancers, and is designed to be preferentially active within the tumor microenvironment [5] - Preclinical data supports CT-202's best-in-class potential, demonstrating potent activity with a favorable pharmacokinetic and safety profile [7] - The company expects to complete regulatory filings to initiate a first-in-human trial for CT-202 in the second quarter of 2026 [7] Group 3: Company Overview - Context Therapeutics aims to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95, and CT-202 [6] - The company is headquartered in Philadelphia and provides updates on its research and clinical trials through its website and social media [6]